My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about BAX

    DEERFIELD, Ill., Aug. 6 /PRNewswire-FirstCall/ -- Baxter International
 Inc. (NYSE:   BAX) announced today a collaboration with DEKA Research &
 Development Corp. and HHD, LLC for the development of a next-generation
 home hemodialysis machine, which will further expand the company's
 leadership in home dialysis therapy.
     "This collaboration highlights Baxter's ongoing commitment to
 innovation in end-stage renal disease (ESRD) treatment," said Bruce
 McGillivray, president, Baxter's Renal business. "In addition, this
 reflects a strategic approach to expediting and enhancing product
 development through targeted partnerships."
     Baxter and DEKA have collaborated on other successful products in the
 past, most notably on the design and development of Baxter's HomeChoice
 automated peritoneal dialysis machine.
     "Home hemodialysis represents the next advancement in home dialysis
 therapy," said McGillivray. "Our global leadership in home dialysis
 therapy, combined with DEKA's new medical product development expertise,
 will allow us to advance this promising technology at a faster pace."
     In connection with the collaboration, Baxter has purchased an option to
 acquire the assets of HHD, LLC and will fund DEKA's related research and
 development activities. Baxter may also make future royalty payments to
 DEKA. In accordance with Generally Accepted Accounting Principles (GAAP),
 Baxter expects to record a special net pre-tax charge of up to $25 million
 (or $0.04 per diluted share) for in-process R&D associated with this
 transaction in the third quarter of 2007.
     About home dialysis therapy
     Dialysis serves as a replacement kidney, removing waste products and
 excess fluid from the body. Conventional in-center hemodialysis, in which
 patients receive treatments for four hours a day three times a week, has
 reached a plateau in the advancement of patient outcomes. The nephrology
 community is now investigating more frequent dialysis of patients as a
 potential breakthrough in improving clinical outcomes.
     A number of small-scale clinical trials have found that more frequent
 and longer dialysis treatments, which are more achievable through at-home
 therapy options, may result in significant short-term and long-term
 clinical benefits for patients such as fewer hospitalizations, better
 anemia control and improved blood pressure management.
     "This will give us the opportunity to offer two forms of highly
 effective at-home dialysis, peritoneal dialysis and home hemodialysis,"
 said Sarah S. Prichard, M.D., vice president of global medical/clinical
 affairs and research for Baxter's Renal business. "In addition, patients
 who are on a home dialysis therapy also see an improvement in their quality
 of life, as they have greater flexibility and control as to when they
 receive their treatment."
     About DEKA and HHD, LLC
     Based in Manchester, NH, DEKA is a research and development company of
 almost 200 employees comprised of engineering, manufacturing and quality
 assurance professionals focused on the development of new technologies that
 span a diverse set of applications. The company was founded in 1982 by Dean
 Kamen, an inventor who holds more than 250 U.S. and foreign patents, many
 of them for innovative medical devices that have expanded the frontiers of
 healthcare worldwide. HHD, LLC owns and licenses certain intellectual
 property assets expected to be utilized in the home hemodialysis program.
     About Baxter
     Baxter International Inc., through its subsidiaries, assists healthcare
 professionals and their patients with the treatment of complex medical
 conditions, including hemophilia, immune disorders, cancer, infectious
 diseases, kidney disease, trauma and other conditions. The company applies
 its expertise in medical devices, pharmaceuticals and biotechnology to make
 a meaningful difference in patients' lives.
     This release includes forward-looking statements concerning
 expectations related to the collaboration between the parties including
 those expectations related to Baxter's leadership in home dialysis therapy
 and its strategic approach to product development, the effect on patients
 of more frequent and longer dialysis treatments, and the financial impact
 of this transaction on Baxter's earnings, including any special charges
 that may be recorded. The statements are based on assumptions about many
 important factors, including the following, which could cause actual
 results to differ materially from those in the forward-looking statements:
 actions of regulatory bodies and other governmental authorities; product
 development risks; changes in laws and regulations; the ability to develop,
 manufacture and sell home dialysis products; product quality or patient
 safety concerns; reimbursement policies of government agencies and private
 payers; demand for and market acceptance risks for new and existing
 products and other technologies; the ability to enforce patents; numerous
 other matters of national, regional and global scale, including those of an
 economic, business, competitive and regulatory nature; and other risks
 identified in the company's most recent filing on Form 10-Q and other SEC
 filings, all of which are available on the company's website. The company
 does not undertake to update its forward-looking statements.
 
 

SOURCE Baxter International Inc.